www.archive-de-2013.com » DE » 4 » 4SC

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".

    Archived pages: 157 . Archive date: 2013-12.

  • Title: www.4sc.de
    Descriptive info: .. Home.. |.. Glossary.. Contact.. Imprint.. Deutsch.. Company.. Product Pipeline.. R&D.. Investors.. News & Media.. Careers.. 4SC Discovery.. Welcome to 4SC.. 4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs.. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.. The Company s pipeline comprises promising products that are in various stages of clinical development and in early-stage research.. 4SC s aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotechnology companies.. 4SC AG is listed on the Frankfurt Stock Exchange (Prime Standard: VSC/ISIN DE0005753818), Germany.. 07 Nov 2013.. Press Release: 4SC announces improved financial  ...   in IBD.. 4SC s lead compound in autoimmune diseases generates a response rate of 88.. 5% for the treatment of patients with Crohn s disease and ulcerative colitis.. more.. Resminostat: best-in-class in 2.. nd.. line HCC.. Resminostat: 8.. 0 months Overall Survival in Phase II SHELTER trial; best-in-class results in 2nd-line liver cancer (HCC) treatment:.. Press Release.. ,.. ILCA 2012 Presentation.. Learn more about 4SC.. Sign up to receive press releases and financial reports.. Overview.. Business Strategy.. Management.. Clinical.. Indications.. Publications & Posters.. Business Development.. Oncology.. Autoimmune Diseases.. Technology.. Financial Information.. Financial Reports.. Corporate News.. Ad Hoc Announcements.. Events & Presentations.. Corporate Governance.. Statutory Publications.. Annual General Meeting.. Info Request & Email Alerts.. News.. Awards.. Photos & Logos.. Vacancies.. Graduates/Trainees.. Copyright 2012 4SC AG.. All rights reserved |.. Privacy Policy..

    Original link path: /
    Open archive

  • Title: Glossary | www.4sc.de
    Descriptive info: ›.. A.. B.. C.. D.. E.. F.. G.. H.. I.. J.. K.. L.. M.. N.. O.. P.. Q.. R.. S.. T.. U V.. W.. X Y Z.. 4SCAN.. Patented technology of 4SC which simulates the principle of high throughput screening on the computer in order to generate new molecules for biology and chemistry research.. ACR20.. Improvement in the disease by at least 20% compared to the base value, i.. e.. reduction of 20% in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician s overall assessment of disease activity, patient s overall assessment of disease activity, patient s assessment of pain, C-reactive protein or erythrocyte sedimentation rate in blood, and degree of physical disability in Health Assessment Questionnaire (HAQ) score.. ACR50.. Improvement in the disease by 50% over the base value.. For the parameters, see ACR20.. ACR70.. Improvement in the disease by 70% over the base value.. ACUTE MYELOID LEUKAEMIA.. Malignant form of cancer affecting part of the haemopoietic system.. AE.. Abbreviation for adverse events.. AFS.. Abbreviation for available for sale, one of four categories of financial instruments.. AFVPL.. Abbreviation for at fair value through profit or loss, one of four categories of financial instruments.. AML.. Abbreviation for acute myeloid leukaemia.. ANTI-MITOTIC.. Inhibiting mitosis, i.. cell nucleus division.. APOPTOSIS.. The process of programmed cell death.. This process can be caused by external factors, for example it may be triggered by immune cells, or may be activated due to cellular processes such as a damaged genome.. Apoptosis is actively conducted by the cell s internal components and results in destruction of the cell.. AUTOIMMUNE DISEASE.. Illness that cause the body s immune system to attack its own tissue.. Go to top.. BMBF.. German abbreviation for the German Federal Ministry of Education and Research.. Go to top.. CAGR.. Compound Annual Growth Rate.. The annualised growth rate of an investment over a specifi ed period of time.. CAI.. Abbreviation for colitis activity index; this index is used for determining disease activity in patients suffering from ulcerative colitis.. CDAI.. Abbreviation for Crohn s disease activity index; this index is used for determining disease activity in patients suffering from Crohn s disease.. CHD BANK.. Conrad Hinrich Donner Bank.. CLINICAL STUDIES.. Trials (Phase I through III) in drug development that are conducted in healthy subjects and patients.. CRC.. Abbreviation for colorectal cancer.. CROHN S DISEASE.. Autoimmune disease resulting in chronic inflammation of the intestine.. D O INSURANCE.. Directors Officers insurance.. DAS28.. Disease activity score ; system that serves to measurethe activity of the disease in RA patients based on 28 defined joints.. DHODH.. Dihydroorotate dehydrogenase; enzyme which plays an important role in building DNA in the cell.. DIVERSITY.. Concept of corporate governance, that takes into account the diversity of people and functions among a company s workforce, management and Supervisory Board.. DMARD.. Disease-modifying anti-rheumatic drugs; agents that alter the course and progression of rheumatoid arthritis.. DNA.. Deoxyribonucleic acid is a biological molecule that contains the genetic information in a cell and codes the blueprint for making the proteins.. DOR.. Abbreviation for duration of response.. EG5.. Kinesin spindle protein which plays a role in the distribution of chromosomes to the daughter cells during cell division.. EGFR.. Abbreviation for epidermal growth factor receptor; a transmembrane receptor with intrinsic tyrosine kinase activity that is highly regulated and/ or found in mutated form in many types of tumours, thus leading to uncontrolled cell growth.. ENDPOINT.. General result of a study that evaluates the outcome of the individual steps based on a clinical trial protocol.. ENZYME.. Protein which enables or accelerates chemical reactions in cells by acting as a  ...   g.. in a test tube.. IN VIVO.. Experiments that take place in the living organism, e.. in animal testing.. KINASE.. Protein which controls cellular signal transfer.. LAR.. Abbreviation for loans and receivables, one of four categories of financial instruments.. LUPUS.. Autoimmune disease, frequently accompanied by joint pain similar to rheumatism; inflammation may also occur in the heart, lungs, kidneys and brain.. MEDICAL ETHICS COMMITTEE.. Assessment of ethical and legal aspects of medical research in human beings; the medical ethics committee must approve the commencement of clinical studies.. MS.. Abbreviation for multiple sclerosis.. MULTIPLE SCLEROSIS.. Autoimmune disease of the central nervous system which results in degeneration of the nerve sheath.. NEUROPATHY.. Collective term for nervous system diseases.. ORR.. Abbreviation for objective overall response rate.. OS.. Abbreviation for overall survival.. OUT-LICENSING AGREEMENT.. Granting of a license to a third party to use one or more industrial property rights.. PFS.. Abbreviation for progression free survival.. PFSR.. Abbreviation for progression free survival rate.. PHARMACODYNAMICS.. Study of the efficacy of drugs in a living organism.. PHARMACOKINETICS.. Spatial and temporal distribution of compounds throughout the various tissues of anorganism.. PHASE I.. Clinical trial of a drug conducted in a small number of healthy patients subject to strict controls; serves to test the tolerance, pharmacokinetics, method of administration and safe dose of the compound.. PHASE II.. Clinical trial conducted in a small number of patients subject to strict controls to identify a compound s sudden side effects and risks; determination of the efficacy of the drug and any potential side effects.. PHASE III.. Study conducted in a large number of patients (between several hundred and several thousand) to determine the safety, efficacy and optimum dosage of a drug under real therapeutic conditions.. PRECLINICAL.. Laboratory tests related to a new drug candidate conducted in animals, organs or cell cultures in order to obtain satisfactory evidence that a clinical study is justified and that the drug candidate is classified as safe.. PRIME STANDARD.. Listing segment of Deutsche Börse with clearly defined transparency requirements.. PROOF-OF-CONCEPT.. Milestone proving a drug candidate s efficacy in medical terms, usually in Phase II.. PROTEASOME.. Multi-protein complex for the decomposition of used cellular products.. PROTEIN.. Large complex molecule composed of amino acids.. Proteins are essential to the structure, regulation and function of all organisms; typical proteins include enzymes and antibodies.. RA.. Abbreviation for rheumatoid arthritis.. RECIST CRITERIA.. Abbreviation for response evaluation criteria in solid tumours; guidelines on the evaluation of therapeutic success in solid tumours.. RHEUMATOID ARTHRITIS.. Autoimmune disease of the connective tissue, especially the joints.. ROYALTIES.. Compensation for the use of third-party rights to intellectual property.. Royalties are generally calculated as a certain percentage of the revenue generated from the intellectual property rights.. SAE.. Abbreviation for serious adverse events.. SIC.. Abbreviation for Standing Interpretations Committee.. STEROID.. Class of hormones such as cholesterol which has an anti-inflammatory effect.. TARGET.. Specific biological molecule, e.. an enzyme or receptor, which plays an important role in the origination or development of a disease.. Compounds/drugs develop their therapeutic activity by binding to a target molecule.. TARGETED THERAPIES.. Specific influencing and controlling of signalling pathways in cancer and autoimmune diseases.. TAXOL.. Drug derived from natural cytotoxins.. It inhibits cell growth by attacking the spindle apparatus during cell.. TOXICITY.. Undesirable side effects of a substance depending on its dose.. TOXICOLOGY.. Field of science examining the effects of toxic substances or the toxicity of substances.. TTP.. Abbreviation for time to progression.. TUBULIN STRUCTURE.. Cellular components which play a significant role in cell division, among others.. U.. ULCERATIVE COLITIS.. Chronic inflammatory disease of the mucous membranes of the large intestine.. WHO.. World Health Organization; the United Nations agency responsible for international public health..

    Original link path: /glossary
    Open archive

  • Title: Contact | www.4sc.de
    Descriptive info: 4SC AG.. Am Klopferspitz 19a.. 82152 Planegg-Martinsried.. Germany.. Location / directions.. Fon +49 (0)89 700763-0.. Fax +49 (0)89 700763-29.. www.. 4sc.. com.. For inquiries in line with the.. pharmacovigilance/adverse events.. for our currently ongoing clinical studies, please call our.. emergency contact.. :.. Telephone: + 49 (0)6201 84640 63.. Other Contact Persons:.. Corporate Communications Investor Relations.. Jochen Orlowski.. Head of Corporate Communications Investor Relations.. E-Mail:.. jochen.. orlowski@4sc.. Human Resources.. Ursula Herz.. Human Resources Specialist.. ursula.. herz@4sc.. Business Development.. Dr.. Manfred Gröppel.. Director Business Development.. E-Mail:.. manfred.. groeppel@4sc.. Delivery Contact.. Sylvia Garke-Mayerthaler.. Manager Purchasing.. Sylvia.. Garke-Mayerthaler@4sc..

    Original link path: /contact
    Open archive

  • Title: Imprint | www.4sc.de
    Descriptive info: 82152 Martinsried.. Fon: +49 (0)89 700763-0.. Fax: +49 (0)89 700763-29.. Internet:.. Management Board.. Dipl.. -Kfm.. Enno Spillner, Dr.. Bernd Hentsch, Dr.. Daniel Vitt.. Commercial Register Munich.. HRB 132917.. VAT-ID-No.. DE 211603775.. ISIN.. DE0005753818.. WKN.. 575381.. This website is maintained by.. Copyright.. The contents of this homepage are protected by copyright.. All rights reserved, in particular the rights of reproduction, translation, use in electronic or mechanical systems and the representation of this homepage in any form whatsoever.. This also includes but is not limited to any other systematic evaluation and distribution of the contents of this homepage.. Any use of the texts, programs and images, in whole or in part,  ...   not marked as such, the applicable protection laws remain in full force and effect.. Limitation of Liability.. The contents of this homepage are verified continuously and updated, as required.. No liability will be accepted for any damage arising in direct or indirect connection with the information given in this homepage.. Any use of these Internet pages or of any other link pages referred to from these pages as well as their contents are at the user s own risk.. These Internet pages also include third-party information and refer to other Internet pages.. Wherever possible, this is indicated accordingly.. No liability will be assumed for any information provided by third parties..

    Original link path: /imprint
    Open archive

  • Title: Corporate News 2013 (News & Media) | www.4sc.de
    Descriptive info: News Media.. 2013.. 2012.. 2011.. 2010.. 2009.. 2008.. 2007.. 2006.. 2005.. Photos Logos..

    Original link path: /news-media/corporate-news/2013
    Open archive

  • Title: Corporate News 2013 (Investors) | www.4sc.de
    Descriptive info: Events Presentations.. Info Request Email Alerts..

    Original link path: /investors/corporate-news/2013
    Open archive

  • Title: Ad Hoc Announcements 2010 | www.4sc.de
    Original link path: /investors/adhoc-announcements/2010
    (No additional info available in detailed archive for this subpage)

  • Title: Info Request & Email Alerts | www.4sc.de
    Descriptive info: Please sign me up for email alerts:.. Corporate releases.. Financial reports.. Please send printed materials:.. Annual report 2012.. Future annual reports.. Title :.. *.. Mr.. Ms.. Miss.. Mrs.. First name:.. Last name:.. Email address :.. Company :.. Address:.. :.. City:.. State / Province:.. Post code:.. Country:.. Afghanistan.. Albania.. Algeria.. American Samoa.. Andorra.. Angola.. Anguilla.. Antarctica.. Antigua and Barbuda.. Argentina.. Armenia.. Aruba.. Australia.. Austria.. Azerbaijan.. Bahamas.. Bahrain.. Bangladesh.. Barbados.. Belarus.. Belgium.. Belize.. Benin.. Bermuda.. Bhutan.. Bolivia.. Bosnia and Herzegovina.. Botswana.. Bouvet Island.. Brazil.. British Indian Ocean Territory.. Brunei Darussalam.. Bulgaria.. Burkina Faso.. Burundi.. Cambodia.. Cameroon.. Canada.. Cape Verde.. Cayman Islands.. Central African Republic.. Chad.. Chile.. China.. Christmas Island.. Cocos (Keeling) Islands.. Colombia.. Comoros.. Congo.. Congo, The Democratic Republic of The.. Cook Islands.. Costa Rica.. Cote D'ivoire.. Croatia.. Cuba.. Cyprus.. Czech Republic.. Denmark.. Djibouti.. Dominica.. Dominican Republic.. Ecuador.. Egypt.. El Salvador.. Equatorial Guinea.. Eritrea.. Estonia.. Ethiopia.. Falkland Islands (Malvinas).. Faroe Islands.. Fiji.. Finland.. France.. French Guiana.. French Polynesia.. French Southern Territories.. Gabon.. Gambia.. Georgia.. Ghana.. Gibraltar.. Greece.. Greenland.. Grenada.. Guadeloupe.. Guam.. Guatemala.. Guinea.. Guinea-bissau.. Guyana.. Haiti.. Heard Island and Mcdonald Islands.. Holy See (Vatican City State).. Honduras.. Hong Kong.. Hungary.. Iceland..  ...   of.. Monaco.. Mongolia.. Montserrat.. Morocco.. Mozambique.. Myanmar.. Namibia.. Nauru.. Nepal.. Netherlands.. Netherlands Antilles.. New Caledonia.. New Zealand.. Nicaragua.. Niger.. Nigeria.. Niue.. Norfolk Island.. Northern Mariana Islands.. Norway.. Oman.. Pakistan.. Palau.. Palestinian Territory, Occupied.. Panama.. Papua New Guinea.. Paraguay.. Peru.. Philippines.. Pitcairn.. Poland.. Portugal.. Puerto Rico.. Qatar.. Reunion.. Romania.. Russian Federation.. Rwanda.. Saint Helena.. Saint Kitts and Nevis.. Saint Lucia.. Saint Pierre and Miquelon.. Saint Vincent and The Grenadines.. Samoa.. San Marino.. Sao Tome and Principe.. Saudi Arabia.. Senegal.. Serbia and Montenegro.. Seychelles.. Sierra Leone.. Singapore.. Slovakia.. Slovenia.. Solomon Islands.. Somalia.. South Africa.. South Georgia and The South Sandwich Islands.. Spain.. Sri Lanka.. Sudan.. Suriname.. Svalbard and Jan Mayen.. Swaziland.. Sweden.. Switzerland.. Syrian Arab Republic.. Taiwan, Province of China.. Tajikistan.. Tanzania, United Republic of.. Thailand.. Timor-leste.. Togo.. Tokelau.. Tonga.. Trinidad and Tobago.. Tunisia.. Turkey.. Turkmenistan.. Turks and Caicos Islands.. Tuvalu.. Uganda.. Ukraine.. United Arab Emirates.. United Kingdom.. United States.. United States Minor Outlying Islands.. Uruguay.. Uzbekistan.. Vanuatu.. Venezuela.. Viet Nam.. Virgin Islands, British.. Virgin Islands, U.. S.. Wallis and Futuna.. Western Sahara.. Yemen.. Zambia.. Zimbabwe.. Phone:.. Fax:.. Category:.. Investor - Institutional.. Investor - Retail.. Press.. Business.. Other.. * Required fields..

    Original link path: /investors/info-request-email-alerts
    Open archive

  • Title: Overview (Company) | www.4sc.de
    Descriptive info: Headquartered in Planegg-Martinsried near Munich/Germany, 4SC is an innovative biotech company with a strong focus on research and development.. 4SC discovers and develops targeted small molecule drugs for the treatment of cancer and autoimmune diseases in indications with a high unmet medical need and major economic potential.. In so doing, we wish to offer affected patients treatment options that are more effective and better tolerated to provide a better quality of life and create value for our shareholders, partners and employees.. Our product pipeline comprises promising drug programmes at various stages of clinical development, as well as early-stage research projects.. We  ...   important cell communication patterns that contribute to the development and persistence of cancer and autoimmune diseases.. Through development and marketing partnerships with pharmaceutical and biotech companies, we are bringing our programmes closer to market approval, thus ensuring commercial success.. We are also strengthening our business model by entering into service and research collaborations in the fields of drug discovery and pharmaceutical early-stage research.. 4SC was established in 1997.. The Company consists of the Group parent company 4SC AG and its wholly-owned subsidiary 4SC Discovery GmbH.. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005..

    Original link path: /company/overview
    Open archive

  • Title: Business strategy | www.4sc.de
    Descriptive info: 4SC has set itself the goal of funding its own research and development programmes from the revenue generated from business operations and to become profitable in the long term.. The aim is to bring all therapeutic programmes into phases of development that constitute an attractive basis from which 4SC can secure licensing deals with the pharmaceutical and biotechnology industry.. Sustained cash flows will be established by means of upfront and milestone payments from joint venture partners, complemented by revenue from license fees and royalties, thus making a key contribution to the Company s financing and growth.. By focusing on two indications with high unmet medical needs (oncology and autoimmune diseases), conducting targeted research and using interdisciplinary project teams as well as working with strong partners, 4SC with its comparatively lean structure and modest use of resources can execute its projects and thereby ensure that its business model remains viable in the long term.. 4SC is focused on small-molecules for autoimmune and  ...   the two complementary segments of Discovery Collaborative Business and Development.. The scope of activities in the Development segment, represented by the Group parent company 4SC AG, comprises the later stages of the pharmaceutical development process, i.. clinical development of 4SC s drug candidates.. The segment is working to secure development and marketing partnerships with strong players in the pharmaceutical and biotechnology industry, so as to systematically develop the clinical programmes towards approval.. This approach is intended to enhance development work while simultaneously reducing development risk.. The Discovery Collaborative Business segment, which is represented by 4SC Discovery GmbH, comprises all activities involved in early-stage drug research (drug discovery and optimisation) and its commercialisation.. This segment will press ahead with 4SC s own early-stage research programmes through development and marketing partnerships as well as licensing deals with pharmaceutical and biotechnology companies.. It will also generate additional cashflows from research services and/or collaborations with pharmaceutical and biotechnology companies, thereby strengthening the Group s business model..

    Original link path: /company/business-strategy
    Open archive

  • Title: Product Pipeline (Company) | www.4sc.de
    Descriptive info: 4SC s product pipeline is currently comprised of four compounds in various stages of clinical development as well as several programmes in early research.. It is our goal to work with strong partners from industry and academia to progress our drug programmes along the path to approval.. Please click to enlarge..

    Original link path: /company/pipeline
    Open archive

  • Archived pages: 157